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  Piperacillin （PIPC） was used for the treatment of urinary tract infections due to Serratia marcescens
and the following results were obtained．
  1） There was a close relationship betw；een infection of Serratia marceseens and presence of an indwel－
Iing catheter at the time of treatment．
  2） Bacteriological effectiveness with 1’IPC classified by daily dosage were evaluated as follows；
in the group of 4 g per day， excellent in 6 strains， good in 8 strains and poor in 8 strains and the eMcacy
was 820／6． ln the group of 6 g per day， excellent in 3， good in 4 and poor in 4， and it was 640／．， an，d
in 8 g daily dose， excellent in 2， good in 5 and poor in 3， and the eMcacy was 700／， ． The overall eflicacy
was 740／，．
  3） Bacteriological effectiveness of Gentamicin with daily dose of 80一一120 mg was excellent in
9 strains， good in 4 strains and poor in 6 strains， and the eMcacy was 68 0／o ．
  4） No remarkable side effect was observed in any case．
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  Fig． 1． Chemical structure of piperacillin．
104 和志田。ほか：セラチア感染症・ピペラシリン











Table 1． Relationship between Serratia marceseens
    and presence of an indwelling catheter
    at the time of treatment．
          1ndwelllng catheterUnderlying ． diseases           Yes No
Benign prostatic hyperplasia 26’
End一・stage of concers I O
Cerebrovascular accident 5

























      投与方法および投与量
 1．PIPC投与群
 1日の投与量により次の3群に分けた．
 A群：20％TZ 20 m正にPIPC 29を溶解し， one
shot静注にて1日2回，計4gを投与した．投与期
聞は5～14日平均8．9日であった．








 GMを1回40 mg，1日2，3回（80～120 mg）筋
肉内に投与した．期間は5～7日平均6・2EIであった．
        効果判定基準
 今回の研究では，自覚症状や尿中白血球の変動を効
果判定の指標にすることは困難であったので，尿申細
Table 2．Bacteriological results with PIPC
classified by daily dosage＊＊．

















C ［xceHent 2  Good 5  Poor 3
TotQI Excetlent 8




曇 Number o響5↑roins iso［o量ed
－x Group A ： 2g twice dally
 Group B ： 2g three times daily





















Table 3． Bacteriotogical results of gentamicin．
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にKlebsiella， Proteus， Pseudomonas， Serratiaなどには
CBPG， SBPCよりも強い抗菌性を示すといわれてい
る．さらCC Serratiaに対しては（】BPC， SBPC， ABPC
よりも強い抗菌力がMitsuhashi et al．によって示さ
れている7），
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